The Evaluation of Cardiovascular Risk in Diabetic Patients

S. Kosirova; D. Rubintova; J. Lacka; J. Klimas; T. Foltanova; I. Tumova

doi:10.2478/afpuc-2022-0001

.blurhash-client-img { display: none !important; }

The Evaluation of Cardiovascular Risk in Diabetic Patients

European Pharmaceutical Journal

Volume 69 (2022): Issue 1 (January 2022)

By: S. Kosirova, D. Rubintova, J. Lacka, J. Klimas, T. Foltanova and I. Tumova

Open Access

|Apr 2022

Abstract

AIM

The aim of the study was to evaluate cardiovascular risk in patients with diabetes mellitus type 2 according to gender.

METHODS

The monitoring was designed as a retrospective analysis of data obtained from the documentation of the diabetic outpatients treated with the dipeptidyl peptidase-4 inhibitors (DPP4is) or sodium–glucose co-transporter-2 (SGLT2). Cardiovascular risk was assessed according to UKPDS risk engine.

RESULTS

The levels of HbA1c decreased throughout the whole study. Sixty per cent of patients achieved an HbA1c level <8% after 18 months. Both men and women had similar glycaemic compensation. Men had a significantly higher risk of fatal coronary heart disease (CHD) (p < 0.001), stroke (p < 0.01) and fatal stroke (p < 0.01) compared to women. We found the risk of fatal CHD to be 38-fold higher in men compared to women (p < 0.01).

CONCLUSION

Potential cardiovascular effects of antidiabetic treatment should be clearly defined with possible different effects according to gender. We found a much higher risk in men than women, even when their glycaemic compensation was comparable.

References

ADA. Standards of Medical Care in Diabetes - 2021 Abridged for Primary Care Providers. Clinical Diabetes. 2021;39:14–43.
Search in Google Scholar Back to article
ADA. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S73–S85
Search in Google Scholar Back to article
Almeda-Valdes P, Cuevas-Ramos D, Mehta R, Gomez-Perez FJ, Aguilar-Salinas CA. UKPDS Risk Engine, decode and diabetes PHD models for the estimation of cardiovascular risk in patients with diabetes. Curr Diabetes Rev. 2010;6:1–8.
Search in Google Scholar Back to article
Bell, D. Diabetes therapy and cardiac risk. Cleveland Clinic Journal of Medicine. 2015;82(3):140
Search in Google Scholar Back to article
Bittencourt MS & Hajjar LA. Insulin therapy in insulin resistance: Could it be part of a lethal pathway? Atherosclerosis. 2015;240(2):400–401
Search in Google Scholar Back to article
Campesi I, Franconi F, Seghieri G, Meloni M.. Sex-gender-related therapeutic approaches for cardiovascular complications associated with diabetes. Pharmacological Research. 2017:119:195–207
Search in Google Scholar Back to article
Control Group, Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52:2288–98
Search in Google Scholar Back to article
Currie CJ & Johnson JA.. The safety profile of exogenous insulin in people with type 2 diabetes: Justification for concern. Diabetes, Obesity and Metabolism. 2012:14(1):1–4
Search in Google Scholar Back to article
Davidson JA. SGLT2 inhibitors in patients with type 2 diabetes and renal disease: Overview of current evidence. Postgraduate Medicine, 2019;131(4):251–260
Search in Google Scholar Back to article
Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41:2669–701
Search in Google Scholar Back to article
European Medicines Agency. https://www.ema.europa.eu/en
Search in Google Scholar Back to article
Fadini GP., Bonora BM, Avogaro A. SGLT2 inhibitors and diabetic ketoacidosis: Data from the FDA Adverse Event Reporting System. Diabetologia, 2017;60(8):1385–1389
Search in Google Scholar Back to article
Fei Y, Tsoi MF, Cheung BMY. Cardiovascular outcomes in trials of new antidiabetic drug classes: A network meta-analysis. Cardiovascular Diabetology. 2019:18(1):112
Search in Google Scholar Back to article
Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation 2014;129:e28–292
Search in Google Scholar Back to article
Herman ME, O’Keefe JH, Bell DSH, Schwartz SS.. Insulin Therapy Increases Cardiovascular Risk in Type 2 Diabetes. Progress in Cardiovascular Diseases. 2017:60(3):422–434 https://doi.org/10.1016/j.pcad.2017.09.001
Search in Google Scholar Back to article
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.
Search in Google Scholar Back to article
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577–96.
Search in Google Scholar Back to article
Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. Journal of Diabetes and Its Complications. 2013;27(5):479–484
Search in Google Scholar Back to article
Kashiwagi A, Maegawa H. Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardiorenal protection in the treatment of patients with type 2 diabetes mellitus. Journal of Diabetes Investigation. 2017;8(4):416–427
Search in Google Scholar Back to article
Kautzky-Willer A, Harreiter J, Abrahamian H, Weitgasser R, Fasching P, Hoppichler F, et al. Sex and gender-specific aspects in prediabetes and diabetes mellitus-clinical recommendations. Wien Klin Wochenschr. 2019;131:221–8.
Search in Google Scholar Back to article
Kautzky-Willer A, Harreiter J. Sex and gender differences in therapy of type 2 diabetes. Diabetes Research and Clinical Practice. 2017;131:230–241
Search in Google Scholar Back to article
Kautzky-Willer A, Harreiter J, Pacini G. Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus. Endocrine Reviews. 2016;37(3):278–316
Search in Google Scholar Back to article
Kautzky-Willer A, von Euler M, Oertelt-Prigione S. Editorial: Sex and Gender Aspects in Diabetes. Frontiers in Endocrinology. 2019;10:813
Search in Google Scholar Back to article
Kavaric N, Klisic A, Ninic A. Cardiovascular Risk Estimated by UKPDS Risk Engine Algorithm in Diabetes. Open Med (Wars). 2018;13:610–7.
Search in Google Scholar Back to article
Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, Neil HA, et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke. 2002;33:1776–81.
Search in Google Scholar Back to article
Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, del Cañizo-Gómez FJ. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J Diabetes. 2014;5:444–70.
Search in Google Scholar Back to article
Palmer SC, Tendal B, Mustafa RA, et. al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: Systematic review and network meta-analysis of randomised controlled trials. BMJ (Clinical Research Ed.). 2021;372:m4573
Search in Google Scholar Back to article
Rabizadeh S, Nakhjavani M, Esteghamati A. Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review. Int J Endocrinol Metab. 2019;17.
Search in Google Scholar Back to article
Riddle MC, Ambrosius WT, Brillon DJ et al. (ACCORD) Epidemiologic Relationships Between A1C and All-Cause Mortality During a Median 3.4-Year Follow-up of Glycemic Treatment in the ACCORD Trial. Diabetes Care. 2010;33(5):983–990
Search in Google Scholar Back to article
Santilli F, D’Ardes D, Guagnano MT, Davi G. Metabolic Syndrome: Sex-Related Cardiovascular Risk and Therapeutic Approach. Curr Med Chem. 2017;24:2602–27.
Search in Google Scholar Back to article
Savarese G, Perrone-Filardi P, D’Amore C, Vitale C, Trimarco B, Pani L, et al. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis. International Journal of Cardiology. 2015;181:239–44.
Search in Google Scholar Back to article
Seghieri G, Policardo L, Anichini R, Franconi F, Campesi I, Cherchi S, Tonolo G. The Effect of Sex and Gender on Diabetic Complications. Current Diabetes Reviews. 2017;13(2):148–160
Search in Google Scholar Back to article
Scheen AJ. Cardiovascular Effects of New Oral Glucose-Lowering Agents. Circulation Research. 2018;122(10): 1439–1459
Search in Google Scholar Back to article
Stevens RJ, Kothari V, Adler AI, Stratton IM, United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond). 2001;101:671–9.
Search in Google Scholar Back to article
UKPDS group. (1998). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet. 352(9131):854–865
Search in Google Scholar Back to article
UKPDS. UKPDS Risk Engine: Overview https://www.dtu.ox.ac.uk/riskengine/
Search in Google Scholar Back to article
Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: The pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017;60(2):215–225
Search in Google Scholar Back to article
Wang H, Ba Y, Cai R-C, Xing Q. Association between diabetes mellitus and the risk for major cardiovascular outcomes and all-cause mortality in women compared with men: a meta-analysis of prospective cohort studies. BMJ Open. 2019;9:e024935.
Search in Google Scholar Back to article
Xu J, Rajaratnam R. Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes. Cardiovascular Diabetology. 2017;16:18.
Search in Google Scholar Back to article
Yang L, Fish AF, Zhu Y, Yuan X, Li J, Wang X, et al. Sex differences in 10-year ischemic cardiovascular disease risk prediction in Chinese patients with prediabetes and type 2 diabetes. BMC Cardiovascular Disorders. 2019;19:301.
Search in Google Scholar Back to article
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31–9.
Search in Google Scholar Back to article
Zheng SL, Roddick AJ, Aghar-Jaffar R, Shun-Shin MJ, Francis D, Oliver N, Meeran K. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis. JAMA. 2018;319(15):1580–1591
Search in Google Scholar Back to article
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 2015;373:2117–28
Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.2478/afpuc-2022-0001 | Journal eISSN: 2453-6725

Journal RSS Feed

Language: English

Page range: 1 - 8

Submitted on: Aug 6, 2021

Accepted on: Nov 5, 2021

Published on: Apr 4, 2022

Published by: Comenius University in Bratislava, Faculty of Pharmacy

In partnership with: Paradigm Publishing Services

Publication frequency: 2 issues per year

Keywords:

diabetes,

UKPDS,

coronary heart disease,

stroke,

gender

Related subjects:

Pharmacy,

Pharmacy, other

© 2022 S. Kosirova, D. Rubintova, J. Lacka, J. Klimas, T. Foltanova, I. Tumova, published by Comenius University in Bratislava, Faculty of Pharmacy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Volume 69 (2022): Issue 1 (January 2022)